Group 1 - The financing balance of the North Exchange is approximately one-third of that of the ChiNext, indicating lower investor sentiment and market activity [1][11] - The North Exchange's financing balance reached a historical high of 92.85 billion yuan as of January 14, 2026, with a financing balance of 92.84 billion yuan [11][12] - The North Exchange's financing balance as a percentage of market capitalization was 1.25% in 2025, significantly lower than the ChiNext (3.57%) and the Sci-Tech Innovation Board (2.97%) [15][18] Group 2 - The North Exchange 50 Index reported 1,548.33 points, with a P/E ratio of 64.92X, while the North Exchange specialized and new index reached 2,666.88 points with a P/E ratio of 83.81X [2][32] - The average P/E ratios for key sectors in the North Exchange are as follows: high-end equipment (42.38X), information technology (96.48X), new chemical materials (47.82X), consumer services (49.03X), and biomedicine (37.32X) [39][44] - The North Exchange has seen a significant increase in daily trading volume, with an average of 409.81 billion yuan, up 55.52% from the previous week [31][33] Group 3 - The report recommends focusing on high-performing stocks within the North Exchange 50 and technology growth companies, particularly those with strong new production capabilities and scarcity attributes [46] - Recent IPOs have shown strong performance, with the first new stock of 2026, Kema Materials, experiencing a first-day increase of 371.27% [2][24] - The report highlights the active trading of North Exchange 50 constituent stocks, which generally show higher activity levels in financing and margin trading compared to non-constituent stocks [19][20]

Group 1 - The medical beauty sector increased by 0.18% on January 14, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 151.77, up 0.30%, and Jinbo Biological down 1.14% at 238.58 [1] Group 2 - The net inflow of main funds in the medical beauty sector was 5.91 million yuan, while retail funds saw a net inflow of 12.26 million yuan [1] - The main funds for Ai Meike had a net inflow of 17.77 million yuan, while retail funds had a net inflow of 4.15 million yuan [2] - Jinbo Biological experienced a significant net outflow of main funds at 43.53 million yuan, indicating a negative trend [2]

Group 1 - The medical beauty sector increased by 0.4% on January 12, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] - The trading volume and turnover for Ai Meike were 44,900 shares and 6.76 billion yuan, respectively [1] Group 2 - The net outflow of main funds in the medical beauty sector was 50.50 million yuan, while retail funds saw a net inflow of 24.49 million yuan [1] - The detailed fund flow for individual stocks showed significant net outflows for *ST Meigu and Jinbo Biological, with net outflows of 7.42 million yuan and 39.56 million yuan, respectively [2] - Ai Meike experienced a net outflow of 34.20 million yuan from main funds, indicating a 5.06% decrease in net shareholding [2]

Market Performance - The North Exchange 50 Index increased by 5.82% compared to the previous week, while the Shanghai and Shenzhen 300 Index rose by 2.79% and the ChiNext Index by 3.89%[30] - The average market capitalization of North Exchange A-shares reached 3.197 billion yuan, with a daily average trading volume of approximately 26.13 billion yuan, up 34.57% from the previous week[5] Investment Recommendations - Focus on sectors with high industry prosperity and scarcity, particularly commercial aerospace, robotics, low-altitude economy, energy storage, solid-state batteries, and liquid cooling[40] - The PE ratios for North Exchange A-shares, ChiNext, Shanghai Main Board, Shenzhen Main Board, and Sci-Tech Innovation Board are 48.40, 45.54, 12.69, 24.07, and 78.26 respectively as of January 9, 2026[40] Economic Indicators - The Consumer Price Index (CPI) rose by 0.8% year-on-year in December 2025, marking the highest increase since March 2023[22] - The Producer Price Index (PPI) increased by 0.2% month-on-month in December 2025, but decreased by 1.9% year-on-year[22] Regulatory Developments - The People's Bank of China is expected to implement a prudent monetary policy, emphasizing the need for financial support for economic stability and growth in 2026[11] - The China Securities Regulatory Commission is intensifying efforts to combat financial fraud in the capital market, with 159 cases of financial fraud handled in 2024[18] Industry News - China applied for frequency resources for over 200,000 satellites in December 2025, indicating a significant expansion in the commercial aerospace sector[29] - The United Nations projects global economic growth at 2.7% for 2026, slightly lower than the 2.8% estimated for 2025, amid ongoing macroeconomic uncertainties[26]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 149.91 | 2.69% | 6.91万 | 10.43 Z | | 688363 | 华熙生物 | 46.23 | 2.48% | 6.13万 | 2.81亿 | | 920982 | 锦波生物 | 236.70 | 0.33% | 9061.73 | 2.14亿 | | 000615 | *ST美谷 | 3.34 | -1.18% | 15.25万 | 5124.82万 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 688363 华熙生物 | | 1158.82万 | 4.13% | -1105.93万 | -3.94% | -52.89万 | -0.19% | | 300896 | 爱美客 | 128.81万 ...

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

证券之星消息，1月6日医疗美容板块较上一交易日上涨0.66%，爱美客领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 146.49 | 1.06% | 3.41万 | 4.98 乙 | | 688363 | 华熙生物 | 44.91 | 0.34% | 5.16万 | 2.31亿 | | 920982 | 锦波生物 | 236.12 | -0.22% | 7324.94 | 1.74亿 | | 000615 | *ST美谷 | 3.46 | -0.86% | 13.90万 | 4782.12万 | 从资金流向上来看，当日医疗美容板块主力资金净流出1283.62万元，游资资金净流入772.62万元，散户 资金净流入511.0万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | 主力净占比 游资净流入 ...

证券之星消息，1月5日医疗美容板块较上一交易日上涨2.22%，华熙生物领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 44.76 | 2.47% | 4.79万 | 2.14亿 | | 300896 | 爱美客 | 144.95 | 2.28% | 3.97万 | 5.72亿 | | 920982 | 锦波生物 | 236.64 | 1.26% | 7690.59 | 1.80 Z | | 000615 | *ST美谷 | 3.49 | 0.00% | 11.32万 | 3982.21万 | 从资金流向上来看，当日医疗美容板块主力资金净流入1362.9万元，游资资金净流出704.42万元，散户资 金净流出658.47万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345 ...

从资金流向上来看，当日医疗美容板块主力资金净流出7417.96万元，游资资金净流入4452.13万元，散户 资金净流入2965.84万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入（元） 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | | 105.57万 | 41.13% | -56.92万 | -22.18% | -48.65万 | -18.96% | | 688363 华熙生物 | | -37.49万 | -0.38% | 703.25万 | 7.05% | -665.76万 | -6.67% | | 920982 锦波生物 | | -2340.27万 | -12.47% | -1744.60万 | -9.29% | -285.65万 | -1.52% | | 300896 | 爱美客 | -7486.05万 | -20.24% | 3805.80万 | 10.29% | 3680.25万 | 9.9 ...

截至12月26日，北交所融资融券余额合计79.79亿元，较前一交易日增加2788.90万元，其中，融资余额 79.79亿元，较前一交易日增加2791.38万元，融券余额为25.02万元，较前一交易日减少2.48万元。 | 920571 | 国航远 | -0.69 | 5087.27 | 166.37 | 1.80 | 交通运 | | --- | --- | --- | --- | --- | --- | --- | | | 洋 | | | | | 输 | | 920665 | 科强股 | -2.31 | 1443.47 | 164.82 | 1.52 | 基础化 | | | 份 | | | | | 工 | | 920719 | 宁新新 | 0.00 | 1027.46 | 163.70 | 1.08 | 基础化 | | | 材 | | | | | 工 | | 920068 | 天工股 | -4.79 | 3747.19 | 157.51 | 2.98 | 有色金 | | | 份 | | | | | 属 | | 920418 | 苏轴股 | | | | | 汽车 | | | 份 | -1.72 | 8246.2 ...